Superparamagnetic Nanoparticles for Blood Pathogen Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pathogen inactivation in whole blood are not effective against a broad spectrum of viruses, including both enveloped and non-enveloped types, and often result in denaturation of therapeutic proteins or residual toxicity, posing risks for transfusion-transmitted infections and bioterrorism threats.
Innovation Solution
The use of superparamagnetic nanoparticles (SPN) coated with chemiluminescence reagents and broad-spectrum antiviral therapeutics (CAT) that interact with enzymes to produce light signals, activating photodynamic compounds to inactivate pathogens in whole blood, with a magnetic field aiding in nanoparticle mixing and removal, ensuring minimal disruption to biological integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional pathogen inactivation methods are used, then some pathogens are inactivated, but they are not effective against a broad spectrum of viruses including both enveloped and non-enveloped types
Solution Approach 1:
The patent employs a multi-component system comprising superparamagnetic nanoparticles coated with chemiluminescence reagents and broad-spectrum antiviral therapeutics. This universal system is designed to inactivate multiple types of pathogens (enveloped viruses, non-enveloped viruses, bacteria, and parasites) through a single treatment protocol, achieving both broad adaptability and reliable effectiveness across diverse pathogen types.
2Reliability
If conventional pathogen inactivation methods are used, then pathogens are inactivated, but they result in denaturation of therapeutic proteins
Solution Approach 1:
The patent utilizes chemiluminescence reagents that generate light signals to activate photodynamic compounds, enabling pathogen inactivation through photochemical reactions rather than thermal or harsh chemical treatments. This parameter change in the inactivation mechanism preserves therapeutic protein integrity while maintaining effective pathogen inactivation, as the mild photochemical conditions do not denature proteins.
3Reliability
If conventional pathogen inactivation methods are used, then pathogens are inactivated, but they result in residual toxicity
Solution Approach 1:
The patent employs superparamagnetic nanoparticles that can be easily removed from the treated blood products using an external magnetic field. The nanoparticles, along with any associated chemical reagents, are extracted from the final product, eliminating residual toxicity while maintaining effective pathogen inactivation. This extraction step ensures the safety of the treated blood products for transfusion.
4Reliability
If rigorous screening and testing of blood donors is performed, then transfusion safety is improved, but the risk of transmission during the window period remains
Solution Approach 1:
The patent applies pathogen inactivation treatment to blood products before transfusion, regardless of the donor's screening status. This preliminary action addresses the window period risk by inactivating pathogens that may be present but not yet detectable by routine screening tests. The treatment is applied proactively to all blood products, eliminating the vulnerability associated with the serological window period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the risk of transfusion-mediated transmission of known and unknown pathogens, eliminates the need for downstream pathogen clearance steps, and retains biological activity of blood products, providing a safer blood supply by inactivating both enveloped and non-enveloped viruses, bacteria, and parasites.
Implementation Method 1
a changing magnetic field causes rapid mixing of the nanoparticles into the whole blood to minimize diffusion-limitations and shorten processing times
Implementation Method 2
Chemiluminescence reagents on nanoparticles interact with specific enzymes in solution to produce an in situ light signal for activate photodynamic broad-spectrum anti-viral compounds
Implementation Method 3
a magnetic field is used to remove the nanoparticles and chemical reagents from the whole blood after pathogen inactivation
Data Source
AI summary
A method and apparatus for reducing or inactivating pathogens in units of whole blood. A plurality of superparamagnetic nanoparticles (SPN) is coated with a mixture of chemiluminescence light-generating compounds and photodynamic broad-spectrum anti-viral compounds, and the mixture in introduced into a bag of whole blood. A rapidly-changing electromagnetic field is applied to the bag to cause uniform distribution of the nanoparticles within the whole blood throughout all regions of the blood bag, including the opaque interior of the bag. The blood is processed for a predetermined processing time period, during which the chemiluminescence light activates the broad-spectrum antiviral capacity of the photodynamic compounds to achieve reduction or inactivation of pathogens throughout the blood bag. After the processing time is elapsed, the nanoparticles are removed from the processed blood by a magnetic field. The processed blood may be washed by conventional means, to remove residual reagents, and transferred into a new, sterile blood bag.